TargetBeta
ENPP3
ectonucleotide pyrophosphatase/phosphodiesterase 3 · also PD-IBETA, gp130RB13-6, B10, CD203c · CD molecules
3 programs in company-led studies act on ENPP3, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387 | Johnson & Johnson | phase 1 | 11 running | CD3E | a judged reading |
| GTX-B001rule | Granular Therapeutics | phase 1 | 11 running | – | the studies' text |
| JNJ-89862175 | Johnson & Johnson | phase 1 | 11 running | – | a judged reading |
Also acted on by the same programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 15, 2026JNJ-89862175 · Johnson & Johnson · phase 1 · NCT07223125
- Mar 16, 2027Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387 · Johnson & Johnson · phase 1 · NCT06178614
- Aug 2027GTX-B001 · Granular Therapeutics · phase 1 · NCT07181369
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.